Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Liabilities and Shareholders Equity (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $621.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 28.69% to $621.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 billion, a 17.45% decrease, with the full-year FY2025 number at $621.3 million, down 28.69% from a year prior.
  • Liabilities and Shareholders Equity was $621.3 million for Q4 2025 at Relay Therapeutics, down from $670.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q3 2022 to a low of $621.3 million in Q4 2025.
  • A 5-year average of $863.0 million and a median of $857.6 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 105.27% in 2021, then fell 28.69% in 2025.
  • Relay Therapeutics' Liabilities and Shareholders Equity stood at $1.0 billion in 2021, then increased by 9.06% to $1.1 billion in 2022, then fell by 23.26% to $844.0 million in 2023, then grew by 3.24% to $871.3 million in 2024, then dropped by 28.69% to $621.3 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Liabilities and Shareholders Equity are $621.3 million (Q4 2025), $670.0 million (Q3 2025), and $728.8 million (Q2 2025).